# US 2016/0256440 A1 · Multisubstituted aromatic compounds as inhibitors of thrombin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256440 A1
- Document ID: US20160256440A1
- Status: Published application
- Kind: A1
- Application number: 15/155,954
- Filed: 2016-05-16
- Published: 2016-09-08
- Earliest claimed: 2010-03-30
- Applicants: Verseon Corporation
- Inventors: Kevin Michael Short; Son Minh Pham; David Charles Williams; Somalee Datta
- Web page: https://patentgrep.com/patent/US20160256440A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/415: 1,2-Diazoles
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 249/14: Nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

## Claims

### Claim 1

A method for treating and/or preventing a disease or disorder in a subject, comprising administering a compound to a subject in need thereof in an amount effective to treat or prevent said disease or disorder, wherein the compound has the following formula:
or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;
wherein
ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl;
L1, L2 and L3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
L4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
R1, R2 and R3 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is absent, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L4 is absent, then R4 is absent; and
R5 is independently hydrogen, or substituted or unsubstituted alkyl.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound has the following formula:
wherein
L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —NHSO2—, or —NR5—;
L2 is a bond;
L3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
L4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
R1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has a substituent group selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has a substituent group selected from the group consisting of oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;
R3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl, and
R5 is independently hydrogen, or substituted or unsubstituted alkyl.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said disease or disorder is a thrombotic disorder and/or involves a blood clot thrombus or the potential formation of a blood clot thrombus.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said thrombotic disorder comprises acute coronary syndrome, thromboembolism, and/or thrombosis.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the thromboembolism comprises venous thromboembolism, arterial thromboembolism, and/or cardiogenic thromboembolism.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the venous thromboembolism comprises deep vein thrombosis and/or pulmonary embolism.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the deep vein thrombosis and/or pulmonary embolism occurs following a medical procedure.

### Claim 8 (depends on 3)

The method according to claim 3, wherein said thrombotic disorder involves dysfunctional coagulation or disseminated intravascular coagulation.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the subject is undergoing percutaneous coronary intervention (PCI).

### Claim 10 (depends on 3)

The method according to claim 3, wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves stroke and/or one or more transient ischemic attacks (TIA).

### Claim 11 (depends on 10)

The method according to claim 10, wherein said thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus further involves stroke and wherein the subject has non-valvular atrial fibrillation.

### Claim 12 (depends on 3)

The method according to claim 3, wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves pulmonary hypertension.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the pulmonary hypertension is caused by one or more left heart disorder and/or chronic thromboembolic disease.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the pulmonary hypertension is associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.

### Claim 15 (depends on 1)

The method according to claim 1, wherein said disease or disorder comprises fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the disease or disorder involves recurrent cardiac events after myocardial infarction.

### Claim 17 (depends on 5)

The method according to claim 5, wherein the venous thromboembolism is associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the one or more risk factors comprise a previous venous thromboembolism.

### Claim 19 (depends on 5)

The method according to claim 5, wherein the cardiogenic thromboembolism is due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the detached thrombus is in the brain (ischemic stroke).

### Claim 21 (depends on 20)

The method according to claim 20, wherein the detached thrombus causes a transient ischemic attack (TIA).

### Claim 22 (depends on 19)

The method according to claim 19, wherein the cardiogenic thromboembolism is due to non-valvular atrial fibrillation.

### Claim 23 (depends on 4)

The method according to claim 4, wherein the thrombosis is arterial thrombosis.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the arterial thrombosis is due to one or more underlying atherosclerotic processes in the arteries.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the one or more underlying atherosclerotic processes in the arteries obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).

### Claim 26 (depends on 1)

The method according to claim 1, wherein the treatment or prevention comprises an adjunct therapy.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the subject has myocardial infarction, and the adjunct therapy is in conjunction with thrombolytic therapy.

### Claim 28 (depends on 26)

The method according to claim 26, wherein the subject has unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy is in combination with antiplatelet therapy.

### Claim 29 (depends on 26)

The method according to claim 26, wherein the subject has non-valvular atrial fibrillation, and the adjunct therapy is in conjunction with other therapies.
